$54.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
PT-141 is examined in research settings as a melanocortin receptor agonist peptide, structurally derived from α-melanocyte-stimulating hormone (α-MSH). Research involving PT-141 focuses on peptide–receptor binding behavior, melanocortin signaling pathways, and neuropeptide communication mechanisms under controlled laboratory conditions.
$54.99
Synthetic Melanocortin Receptor Agonist Peptide
PT-141, also known as Bremelanotide, is a synthetic peptide supplied exclusively for laboratory and analytical research purposes. This compound is studied in controlled research environments for its interaction with melanocortin receptors and its role in central nervous system signaling pathway research models.
Each batch of PT-141 is independently third-party tested to verify identity and purity, supporting accuracy and reproducibility in scientific research applications.
PT-141 is studied in laboratory and preclinical research environments to better understand melanocortin receptor signaling and neuropeptide-mediated communication pathways. Researchers examine this compound to explore:
As a modified peptide analog, PT-141 provides a controlled model for studying melanocortin system signaling behavior at the molecular level.
In experimental models, PT-141 interacts with melanocortin receptors, which are G protein–coupled receptors involved in intracellular signaling cascades. Research focuses on signal initiation, receptor activation patterns, and downstream pathway coordination within controlled laboratory systems.
These investigations are mechanistic and exploratory and do not imply neurological, behavioral, or physiological outcomes.
PT-141 supplied by ResearchChemical.com is produced under controlled peptide synthesis conditions to support compound integrity, purity, and reproducibility.
Manufacturing and verification standards include:
These measures ensure transparency and reliability for laboratory research use.
Laboratory supplies and dilution solutions are not included.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
Store PT-141 in a cool, dry environment away from direct light. Refrigerate after reconstitution, if applicable, to maintain peptide stability. Avoid repeated freeze-thaw cycles and follow standard laboratory handling protocols to prevent contamination or degradation.
By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
PT-141 is:
The information provided on this page is for educational and informational purposes only and should not be interpreted as medical advice. ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled research environments. It is the purchaser’s responsibility to ensure compliance with all applicable laws and regulations.
The cost of PT-141 may vary depending on the supplier, formulation (injections or nasal spray), and quality. Prices may depend on factors such as purity and quantity purchased.
Look for suppliers like Research Chemical who emphasis high quality standards of practice.
No. PT-141 is not intended for therapeutic, cosmetic, or personal use. It is supplied exclusively for laboratory and analytical research.
PT-141 effects can last for several hours after administration. In clinical trials, the peptide has demonstrated a lasting impact on sexual desire and sexual activity, with an effective response noted within a few hours after administration to test subjects.
The PT-141 peptide has been studied in research for female sexual dysfunction disorder, including hypoactive sexual desire disorder.
Clinical trials have demonstrated a strong correlation in the response to increasing sexual desire and improving sexual behavior in premenopausal women.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
By purchasing from ResearchChemical.com, you acknowledge that you are acquiring research chemicals intended solely for scientific investigation.
PT-141 is:
The information provided on this page is for educational and informational purposes only and should not be interpreted as medical advice. ResearchChemical.com assumes no liability for misuse, improper handling, or use outside of controlled research environments. It is the purchaser’s responsibility to ensure compliance with all applicable laws and regulations.
1. Clayton, A. H., Althof, S. E., Kingsberg, S., DeRogatis, L. R., Kroll, R., Goldstein, I., … & Portman, D. J. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Women’s Health, 12(3), 325-337.
2. Diamond, L. E., Earle, D. C., Heiman, J. R., Rosen, R. C., Perelman, M. A., & Harning, R. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT‐141), a melanocortin receptor agonist. The journal of sexual medicine, 3(4), 628-638.
3. Safarinejad, M. R., & Hosseini, S. Y. (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. The Journal of urology, 179(3), 1066-1071.
4. LINKS, G., LINKS, A., & BOOKS, P. Female Libido Enhancer–Bremelanotide.
5. Rössler, A. S., Pfaus, J. G., Kia, H. K., Bernabé, J., Alexandre, L., & Giuliano, F. (2006). The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacology Biochemistry and Behavior, 85(3), 514-521.
6. Safarinejad MR, et al. Safety and efficacy of PT-141 in the treatment of female SD. Urology. 2018;111: 142-148. doi: 10.1016/j.urology.2017.08.063.
7. Diamond, L. E., Earle, D. C., Heiman, J. R., Rosen, R. C., Perelman, M. A., & Harning, R. (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT‐141), a melanocortin receptor agonist. The journal of sexual medicine, 3(4), 628-638.
Please note that the above references provide evidence for the potential benefits of PT 141 Peptide as stated in the product description. For more in-depth information, kindly refer to these scholarly works.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.